pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2008-0-1-116-120pulmo-1755Research ArticleОБЗОРЫREVIEWФункциональный полиморфизм генов регуляторных молекул и цитокинов при нозокомиальной пневмонииFunctional polymorphism of genes of regulatory molecules and cytokines in nosocomial pneumoniaБайгозинаЕ. А.BaygozinaE. A.
г. Омск
СовалкинВ. И.SovalkinV. I.ГУЗ "Областная клиническая больница"Russian FederationОмская государственная медицинская академияRussian Federation20082802200801116120Copyright © Байгозина Е.А., Совалкин В.И., 20082008Байгозина Е.А., Совалкин В.И.Baygozina E.A., Sovalkin V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1755
.
.
ReferencesГромова А.Ю., Кабанова В.И., Казаков А.А. и др. Влияние полиморфизма генов IL-1β и IL-1Rα на эффективность терапии рекомбинантным IL-1β (Беталейкин) больных хроническим вирусным гепатитом С. Цитокины и воспаление 2004; 3: 17–25.Громова А.Ю., Кабанова В.И., Казаков А.А. и др. Влияние полиморфизма генов IL-1β и IL-1Rα на эффективность терапии рекомбинантным IL-1β (Беталейкин) больных хроническим вирусным гепатитом С. Цитокины и воспаление 2004; 3: 17–25.Симбирцев А.С., Громова А.Ю. Функциональный полиморфизм генов регуляторных молекул воспаления. Цитокины и воспаление 2005; 4 (1): 3–10.Симбирцев А.С., Громова А.Ю. Функциональный полиморфизм генов регуляторных молекул воспаления. Цитокины и воспаление 2005; 4 (1): 3–10.Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005; 24 (4): 300–312.Arcaroli J., Fessler M.B., Abraham E. Genetic polymorphisms and sepsis. Shock 2005; 24 (4): 300–312.Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutation in Tlr4 gene. Science 1998; 282: 2085–2088.Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutation in Tlr4 gene. Science 1998; 282: 2085–2088.Schurr J.R., Young E., Byrne P. et al. Central role of Toll-like receptor 4 signaling and host defense in experimental pneumonia caused by gram-negative bacteria. Infect. Immun. 2005; 73: 532–545.Schurr J.R., Young E., Byrne P. et al. Central role of Toll-like receptor 4 signaling and host defense in experimental pneumonia caused by gram-negative bacteria. Infect. Immun. 2005; 73: 532–545.Arbour N.C., Lorenz E., Schutte B.C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000; 25: 187–191.Arbour N.C., Lorenz E., Schutte B.C. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000; 25: 187–191.Lorenz E., Mira J.P., Frees K.L. et al. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 2002; 162: 1028–1032.Lorenz E., Mira J.P., Frees K.L. et al. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 2002; 162: 1028–1032.Child N.J., Yang I.A., Pulletz M.C. et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 2003; 31: 652–653.Child N.J., Yang I.A., Pulletz M.C. et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 2003; 31: 652–653.Barber R.C., Aragaki C.C., Rivera)Chaver F.A. et al. TLR4 and TNF-α polymorphisms are associated with in increased risk for severe sepsis following burn injury. J. Med. Genet. 2004; 41: 808–813.Barber R.C., Aragaki C.C., Rivera)Chaver F.A. et al. TLR4 and TNF-α polymorphisms are associated with in increased risk for severe sepsis following burn injury. J. Med. Genet. 2004; 41: 808–813.Feterowski C., Emmanuilidis K., Miethke T. et al. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003; 109: 426–431.Feterowski C., Emmanuilidis K., Miethke T. et al. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003; 109: 426–431.Lorenz E., Mira J.P., Cornish K.L. et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 2000; 68: 6398–6401.Lorenz E., Mira J.P., Cornish K.L. et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 2000; 68: 6398–6401.Hayashi F., Smith K.D., Ozinsky A. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099–1103.Hayashi F., Smith K.D., Ozinsky A. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 410: 1099–1103.Hawn T.R., Verbon A., Lettinga K.D. et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires, disease. J. Exp. Med. 2003; 198: 1563–1572.Hawn T.R., Verbon A., Lettinga K.D. et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaires, disease. J. Exp. Med. 2003; 198: 1563–1572.Gupta D., Kirkland T.N., Viriyakosol S. et al. CD 14 is a cellactivating receptor for bacterial peptidoglycan. J. Biol. Chem. 1996; 271: 23310–23316.Gupta D., Kirkland T.N., Viriyakosol S. et al. CD 14 is a cellactivating receptor for bacterial peptidoglycan. J. Biol. Chem. 1996; 271: 23310–23316.Landman R., Reber A.M., Sansano S. et al. Function of soluble CD 14 in serum from patients with septic shock. J. Infect. Dis. 1996; 173: 661–668.Landman R., Reber A.M., Sansano S. et al. Function of soluble CD 14 in serum from patients with septic shock. J. Infect. Dis. 1996; 173: 661–668.Burgmann H., Winkler S., Locker G.J. et al. Increased serum concentration of soluble CD 14 is a prognostic marker in gram-positive sepsis. Clin. Immunol. Immunopathol. 1996; 80: 307–310.Burgmann H., Winkler S., Locker G.J. et al. Increased serum concentration of soluble CD 14 is a prognostic marker in gram-positive sepsis. Clin. Immunol. Immunopathol. 1996; 80: 307–310.Gibot S., Cariou A., Drouet L. et al. Association between a genomic polymorphism within the CD 14 locus and septic shock susceptibility and mortality rate. Crit. Care Med. 2002; 30: 969–973.Gibot S., Cariou A., Drouet L. et al. Association between a genomic polymorphism within the CD 14 locus and septic shock susceptibility and mortality rate. Crit. Care Med. 2002; 30: 969–973.Sutherland A.M., Walley K.R., Russell J.A. Polymorphisms in CD 14, mannosebinding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit. Care Med. 2005; 33: 638–644.Sutherland A.M., Walley K.R., Russell J.A. Polymorphisms in CD 14, mannosebinding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit. Care Med. 2005; 33: 638–644.Wunderink R.G., Waterer G.W., Cantor R.M. et al. Tumor necrosis factor gene poiymorphisms and variable presentation and jutcome of community-acquired pneumonia. Chest 2002; 121: 87.Wunderink R.G., Waterer G.W., Cantor R.M. et al. Tumor necrosis factor gene poiymorphisms and variable presentation and jutcome of community-acquired pneumonia. Chest 2002; 121: 87.Mira J.P., Cariou A., Grall F. et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. J. Am. Med. Assoc. 1999; 282: 561–568.Mira J.P., Cariou A., Grall F. et al. Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. J. Am. Med. Assoc. 1999; 282: 561–568.Tang G.J., Huang S.L., Yien H.W. et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care Med. 2000; 28: 2733–2736.Tang G.J., Huang S.L., Yien H.W. et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit. Care Med. 2000; 28: 2733–2736.Di Giovine F.S., Takhsh E., Blakemore A.I. et al. Single base polymorphism at-511 in the human interleukin-1β gene (IL1β). Hum. Mol. Genet. 1992; 1: 450.Di Giovine F.S., Takhsh E., Blakemore A.I. et al. Single base polymorphism at-511 in the human interleukin-1β gene (IL1β). Hum. Mol. Genet. 1992; 1: 450.Pociot F., Molvig J., Wogensen L. et al. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur. J. Clin. Invest. 1992; 22: 396–402.Pociot F., Molvig J., Wogensen L. et al. A TaqI polymorphism in the human interleukin-1β (IL-1β) gene correlates with IL-1β secretion in vitro. Eur. J. Clin. Invest. 1992; 22: 396–402.Fang X.M., Schroder S., Hoeft A. et al. Comparison of two polymorphisms of the unterleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit. Care Med. 1999; 27: 1330–1334.Fang X.M., Schroder S., Hoeft A. et al. Comparison of two polymorphisms of the unterleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit. Care Med. 1999; 27: 1330–1334.Ma P., Chen D., Pan J. et al. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit. Care Med. 2002; 30: 1046–1050.Ma P., Chen D., Pan J. et al. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit. Care Med. 2002; 30: 1046–1050.Vianna R.C., Gomes R.N., Bozza F.A. et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004; 21: 115–120.Vianna R.C., Gomes R.N., Bozza F.A. et al. Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 2004; 21: 115–120.Turnbull I.R., Javadi P., Buchman T.G. et al. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 2004; 21: 121–125.Turnbull I.R., Javadi P., Buchman T.G. et al. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 2004; 21: 121–125.Remick D.G., Bolgos G.R., Siddiqui J. et al. Six at six: interleukin 6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17: 463–467.Remick D.G., Bolgos G.R., Siddiqui J. et al. Six at six: interleukin 6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002; 17: 463–467.Sutherland A.M., Walley K.R., Manocha S. et al. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch. Intern. Med. 2005; 165: 75–82.Sutherland A.M., Walley K.R., Manocha S. et al. The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch. Intern. Med. 2005; 165: 75–82.Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55: 1023–1027.Hull J., Thomson A., Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000; 55: 1023–1027.Baugh J.A., Bucala R. Macrophage migration inhibitory factor. Crit. Care Med. 2002; 30: 27–35.Baugh J.A., Bucala R. Macrophage migration inhibitory factor. Crit. Care Med. 2002; 30: 27–35.Calandra T., Spiegel L.A., Metz C.N. et al. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc. Natl. Acad. Sci. USA 1998; 95: 11383–11388.Calandra T., Spiegel L.A., Metz C.N. et al. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc. Natl. Acad. Sci. USA 1998; 95: 11383–11388.Bozza F.A., Gomes R.N., Japiassu A.M. et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22: 309–313.Bozza F.A., Gomes R.N., Japiassu A.M. et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22: 309–313.Donn R., Alourfi Z., De Benedetti F. et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthr. And Rheum. 2002; 46: 2402–2409.Donn R., Alourfi Z., De Benedetti F. et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthr. And Rheum. 2002; 46: 2402–2409.Gao L.Y.S., Maloney J., Zambelli A. et al. Role of macrophage migration inhibitory factor (MIF) in human and animal models of acute lung injury (ALI) and sepsis: association of a promoter polymorphism and increased gene expression. Am. J. Respir. Crit. Care Med. 2003; 167: 162.Gao L.Y.S., Maloney J., Zambelli A. et al. Role of macrophage migration inhibitory factor (MIF) in human and animal models of acute lung injury (ALI) and sepsis: association of a promoter polymorphism and increased gene expression. Am. J. Respir. Crit. Care Med. 2003; 167: 162.Wattanathum A., Manocha S., Groshaus H. et al. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 2005; 128: 1690–1698.Wattanathum A., Manocha S., Groshaus H. et al. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 2005; 128: 1690–1698.Gallagher P.M., Lowe G., Fitzgerald T. et al. Association of IL-10 polymorphism with severity of illness in communityacquired pneumonia. Thorax 2003; 58: 154–156.Gallagher P.M., Lowe G., Fitzgerald T. et al. Association of IL-10 polymorphism with severity of illness in communityacquired pneumonia. Thorax 2003; 58: 154–156.Gong M.N., Thompson B.T., Williams P.L. et al. Interleukin-10 polymorphism in position 1082 and acute respiratory distress syndrome. Eur. Respir. J. 2006; 27: 674–681.Gong M.N., Thompson B.T., Williams P.L. et al. Interleukin-10 polymorphism in position 1082 and acute respiratory distress syndrome. Eur. Respir. J. 2006; 27: 674–681.Shu Q., Fang X., Chen Q. et al. IL-10 polymorphism is associated with increased incidence of severe sepsis. Chin. Med. J. (Engl.). 2003; 116: 1756–1759.Shu Q., Fang X., Chen Q. et al. IL-10 polymorphism is associated with increased incidence of severe sepsis. Chin. Med. J. (Engl.). 2003; 116: 1756–1759.Schaaf B.M., Boehmke F., Esnaashari H. et al. Pneumococcal septic shock is associated with the interleukin-10 -1082 gene promoter polymorphism. Am. J. Respir. Crit. Care Med. 2003; 168: 476–480.Schaaf B.M., Boehmke F., Esnaashari H. et al. Pneumococcal septic shock is associated with the interleukin-10 -1082 gene promoter polymorphism. Am. J. Respir. Crit. Care Med. 2003; 168: 476–480.Blakemore A.I., Cox A., Gonzalez A.M. et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum. Genet. 1996; 97: 369–374.Blakemore A.I., Cox A., Gonzalez A.M. et al. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. Hum. Genet. 1996; 97: 369–374.Hurme M., Santtila S. IL-1 receptor antagonist (IL-1Rα) plasma levels are coordinately regulated by both IL-1Rα and IL-1β genes. Eur. J. Immunol. 1998; 28: 2598–2602.Hurme M., Santtila S. IL-1 receptor antagonist (IL-1Rα) plasma levels are coordinately regulated by both IL-1Rα and IL-1β genes. Eur. J. Immunol. 1998; 28: 2598–2602.Arnalich F., Lopez)Maderueloi D., Codoceo R. et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin. Exp. Immunol. 2002; 127: 331–336.Arnalich F., Lopez)Maderueloi D., Codoceo R. et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin. Exp. Immunol. 2002; 127: 331–336.Waterer G.W., Wunderink R.G. Science review: genetic variability in the systemic inflammatory response. Crit. Care 2003; 7 (4): 308–314.Waterer G.W., Wunderink R.G. Science review: genetic variability in the systemic inflammatory response. Crit. Care 2003; 7 (4): 308–314.
The authors declare that there are no conflicts of interest present.